Codiak Reports Positive Initial Data for exoSTING™ Phase 1/2 Trial Indicating Tolerability, Immune Activation, and Evidence of Tumor Shrinkage in Injected and Non-Injected Tumors in the First Three Dose Escalation Cohorts
– exoSTING resulted in localized STING pathway activation and dose-dependent immune activation – – Intratumoral…
New Survey Highlights Gap Between Perceived AI Readiness And Tested Disaster Recovery Capability
Syngenta Deploys Tetra OS to Accelerate Scientific Discovery Through Industrial-Scale Data Automation